Brighton Jones LLC Invests $208,000 in Glaukos Co. (NYSE:GKOS)

Brighton Jones LLC acquired a new stake in Glaukos Co. (NYSE:GKOS) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,761 shares of the medical instruments supplier’s stock, valued at approximately $208,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC lifted its position in Glaukos by 54.8% in the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its position in shares of Glaukos by 5,860.0% in the first quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 1,465 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after buying an additional 486 shares during the period. Fifth Third Wealth Advisors LLC acquired a new position in Glaukos in the 2nd quarter valued at $187,000. Finally, Cetera Advisors LLC bought a new position in shares of Glaukos during the first quarter worth approximately $213,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insiders Place Their Bets

In related news, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the sale, the director now owns 30,119 shares in the company, valued at $3,614,280. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares in the company, valued at approximately $3,614,280. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the completion of the transaction, the director now owns 32,336 shares of the company’s stock, valued at $4,225,345.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,500 shares of company stock valued at $5,099,000. 6.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GKOS shares. Stifel Nicolaus raised their price objective on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Needham & Company LLC upped their target price on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. StockNews.com cut shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Friday, August 30th. BTIG Research raised their price target on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Finally, Wells Fargo & Company boosted their price objective on Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.82.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $127.78 on Monday. The firm’s 50-day moving average is $124.89 and its 200 day moving average is $111.72. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of -44.37 and a beta of 1.03. Glaukos Co. has a 12 month low of $59.22 and a 12 month high of $136.60.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.52). Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The business had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. During the same period last year, the business posted ($0.55) EPS. The business’s revenue was up 19.0% compared to the same quarter last year. Research analysts predict that Glaukos Co. will post -2.18 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.